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Abstract
Engagement of T-cell immunoglobulin mucin (Tim)-1 on T cells with its ligand, Tim-4, on antigen presenting cells delivers
positive costimulatory signals to T cells. However, the molecular mechanisms for Tim-1-mediated regulation of T-cell
activation and differentiation are relatively poorly understood. Here we investigated the role of Tim-1 in T-cell responses
and allograft rejection using recombinant human Tim-1 extracellular domain and IgG1-Fc fusion proteins (Tim-1-Fc). In vitro
assays confirmed that Tim-1-Fc selectively binds to CD4
+ effector T cells, but not dendritic cells or natural regulatory T cells
(nTregs). Tim-1-Fc was able to inhibit the responses of purified CD4
+ T cells that do not express Tim-4 to stimulation by anti-
CD3/CD28 mAbs, and this inhibition was associated with reduced AKT and ERK1/2 phosphorylation, but it had no influence
on nTregs. Moreover, Tim-1-Fc inhibited the proliferation of CD4
+ T cells stimulated by allogeneic dendritic cells. Treatment
of recipient mice with Tim-1-Fc significantly prolonged cardiac allograft survival in a fully MHC-mismatched strain
combination, which was associated with impaired Th1 response and preserved Th2 and nTregs function. Importantly, the
frequency of Foxp3
+ cells in splenic CD4
+ T cells was increased, thus shifting the balance toward regulators, even though
Tim-1-Fc did not induce Foxp3 expression in CD4
+CD25
2 T cells directly. These results indicate that Tim-1-Fc can inhibit T-
cell responses through an unknown Tim-1 binding partner on T cells, and it is a promising immunosuppressive agent for
preventing allograft rejection.
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Introduction
T-cell immunoglobulin mucin (Tim) proteins represent a newly
discoveredfamilyofmoleculesthat playcriticalrolesinregulation of
T helper cell 1 (Th1) and Th2 immune responses. Tim-1 protein
belongs to a family of cell surface glycoproteins that modulate T-cell
immune responses[1,2,3]. Ligation of Tim-1 molecule on T cells
with Tim-4, a ligand for Tim-1 on mature dendritic cells (DCs) and
macrophages, transmits a stimulatory signal in collaboration with
the conventional TCR-dependent signal 1 and results in enhance-
ment of T-cell proliferation, cytokine production and abrogation of
tolerance[4,5,6,7,8,9]. However, the mechanisms for immune
regulation by Tim-1 and Tim-4 are more complex than initially
expected.Recent studies showedthat Tim-4-Ig mayeitherstimulate
or inhibit T-cell proliferation depending on its concentration[4].
Moreover, Tim-4-Ig was demonstrated to inhibit naive mouse
CD4
+T-cellactivationthroughaligandotherthanTim-1,and such
an inhibitory effect of Tim-4-Ig was specific to naive T cells, and the
effect disappeared in pre-activated T cells[10]. This suggests the
possibility that the opposite effect of Tim-4-Ig on T-cell activation
observed in the previous study[4] could be resulted from
engagement with different receptors on T cells. On the other hand,
anti-Tim-1 mAbs were also found to mediate either a stimulatory or
an inhibitory effect on T-cell activation depending on their binding
affinity to Tim-1[11,12]. Thus, further elucidation of the role of
Tim-1 in regulating T-cell responses is highly important for
developing novel therapeutic strategies targeting Tim-1 for the
treatment of autoimmune diseases and allograft rejection.
To further investigate the role of Tim-1 in T cell responses and
allograft rejection, we expressed and purified recombinant human
Tim-1 extracellular region and IgG1 Fc tail fusion proteins (Tim-
1-Fc). We show that Tim-1-Fc selectively bind to CD4
+ effector T
cells (Teffs), but not DCs or natural regulatory T cells (nTregs).
Interestingly, Tim-1-Fc significantly inhibited anti-CD3/CD28-
stimulated proliferation and activation of purified CD4
+ T cells
that do not express Tim-4. Such an inhibitory effect of Tim-1-Fc
was associated with decreased phosphorylation of AKT and
ERK1/2, but the proliferation of nTregs was not inhibited.
Moreover, Tim-1-Fc also inhibited allogeneic mixed lymphocyte
reaction (allo-MLR) in vitro. Treatment with Tim-1-Fc success-
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cardiac transplantation model, this was associated with impaired
Th1 response and preserved Th2 and nTregs function. Impor-
tantly, the proportion of Foxp3
+ cells in splenic CD4
+ T cells was
increased, thus shifting the balance toward regulators, although
Tim-1-Fc didn’t induce Foxp3 expression in CD4
+CD25
- T cells
directly. These data indicate that Tim-1-Fc suppresses alloimmune
responses not by blocking Tim-1 engagement with Tim-4 on DCs
as previously indicated[2,4,13], but by interacting with a novel
unknown ligand that is expressed on Teffs.
Materials and Methods
Animals
Male C57BL/6 (B6, H-2
b), BALB/c (H-2
d) and C3H (H-2
k)
mice (aged 8–10 weeks) were purchased from Shanghai Bikai
Laboratory Animal Technology CO. LTD (Shanghai, China). All
animals were housed under specific pathogen-free conditions in a
12 h day/night rhythm with free access to food and water ad
libitum, and received humane care in accordance with interna-
tional guidelines and the national law. The animal protocol of this
study was approved by the Animal Care and Use committee of the
Second Military Medical University (Permit Number. 08–0086).
All surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Antibodies and reagents
Magnetic separation system and mouse CD4
+, CD4
+CD25
+
regulatory T cells (Tregs) isolation kits were products of Miltenyi
Biotech. FITC-labeled anti-CD4 mAbs, specific rat IgG isotype
control mAbs, PE-labeled anti-CD25, CD69 and Tim-4 mAbs
were purchased from BD PharMingen (San Diego, CA).
Functional anti-Tim-4 mAb was from Biolegend. Mouse Treg
staining Kit (Foxp3 FJK-16s APC; CD4 FITC; CD25 PE) and
ELISA kits for measuring mouse IL-2, IFN-c, IL-4 and IL-10 were
purchased from eBioscience. Human IgG1 (hIgG1) was from
Calbiochem. Recombinant human TGF-b1 was product of
PeproTech. The primary antibody (Rabbit) directed against p-
AKT, p-ERK1/2 and ERK1/2 were purchased from Cell
Signaling (Beverly, MA, USA).
Preparation of recombinant Tim-1-Fc
Extracellular human Tim-1 cDNA was spliced with hinge-CH2-
CH3 domains of IgG1 cDNA and cloned into the pcDNA3.1
mammalian expression vector (Invitrogen, Carlsbad, CA) contain-
ing a mouse Igk secretion signal. Then the recombinant plasmid
was transfected into CHOK1 cells to establish a stable line
expressing Tim-1-Fc. Tim-1-Fc proteins were purified from
CHOK1 cell culture supernatants with a Ni
2+ affinity column
(Qiagen, Valencia, CA, USA). Protein purity was assessed by
Coomassie Blue staining after SDS-PAGE analysis using a 4,20%
Tris/glycine gradient gel. Immunoblot analysis was performed
with mouse anti-human IgG1 Fc mAb (ARP American Research
Products, Inc.) and rat anti-mouse mAb conjugated to horseradish
peroxidase (Invitrogen), followed by enhanced chemiluminescence
(Amersham Biosciences, Piscataway, NJ, USA). The molecular
weight of Tim-1-Fc was about 62KD (Figure S1). Protein
concentrations were determined using the Bradford reagent (Bio-
Rad, Hercules, CA, USA). Endotoxin was then tested using the
end-point colorimetric method (Cambrex Bio Science Walkers-
ville, Walkersville, MD, USA) and found to have ,1EU/mg.
Preparation of bone marrow-derived DCs and splenic T
cells
BALB/c (H-2
d) mouse bone marrow-derived dendritic cells
(DCs) were prepared as described[14]. CD4
+ T cells were purified
using the magnetic separation system according to the manufac-
turer’s recommendations. Briefly, mouse spleen cells were
prepared, incubated with CD4-microbeads for 20 min at 4uC,
and then isolated by positive selection over a magnetic column.
For isolation of CD4
+CD25
2 and CD4
+CD25
+ T cells[15,16],
mouse spleen cells were first depleted of CD4-negative cells by
MACS separation system using a cocktail of biotin-conjugated
antibodies against CD8 (Ly-2), CD11b (Mac-1), CD45R (B220),
CD49b (DX5), and Ter-119 in combination with anti-biotin
microbeads. The purified CD4
+ spleen cells were then used to
isolate CD4
+CD25
2 and CD4
+CD25
+ cells by positive selection
using CD25-PE and anti-PE microbeads. The purity of all isolated
T cell subsets was .95% as determined by flow cytometry (FCM).
Measurement of Tim-1-Fc binding activity to T cells and
DCs
Unstimulated or stimulated DCs, CD4
+CD25
2 and
CD4
+CD25
+ T cells were incubated with 5 mg/ml Tim-1-Fc or
hIgG1 and marked by mouse anti-human IgG1 Fc-FITC (Beck-
man Coulter), followed by FCM. Besides, anti-Tim-4 mAbs
(10 mg/ml), which has been demonstrated to be able to block the
binding of mouse Tim-1-Ig to Tim-4 (Figure S2) was added.
T cells activation, proliferation and division assays
Ninety-six-well flat bottom Nunc plates (Rochester, NY, USA)
were pre-coated with 2 mg/ml of anti-mouse CD3 mAb and 1 mg/
ml of anti-mouse CD28 mAb. After washed with PBS, CD4
+ T
cells (2610
5/well) were plated in RPMI1640 medium supple-
mented with 10% FBS and phosphate buffered saline (PBS) or
hIgG1 control or Tim-1-Fc (at a different final concentration of 1,
5o r1 0mg/ml), and incubated in 5% CO2 at 37uC for 72 h.
3H
thymidine (1 mCi/well, Amersham Pharmacia Biotech, UK) was
added to the culture for the final 18 h and T cell proliferation was
measured by
3H thymidine incorporation using a liquid scintilla-
tion counter (Wallac, Turku, Finland). The supernatants were
collected for cytokine detection. For cell division measurement,
freshly isolated CD4
+ T cells were labeled with CSFE (Molecular
Probes, Eugene, OR, USA) according to the manufacturer’s
instructions, cultured in anti-CD3 and anti-CD28 mAbs-pre-
coated plate as described above, and then analyzed by FCM 72 h
later. To determine the effect of Tim-1-Fc on nTregs, purified
CD4
+CD25
+ T cells (2610
5/well) were plated in the anti-CD3
and anti-CD28 mAbs (100 ng/ml for each) pre-coated plate in the
presence of IL-2 (200 IU/ml)[17] with or without Tim-1-Fc at
different final concentrations (1, 5 or 10 mg/ml). Then the
proliferation and Foxp3 expression of nTregs were analyzed by
3H thymidine incorporation and SYBR green real-time polymer-
ase chain reaction (RT-PCR).
Measurement of Tim-4 expression on T cells
Tim-4 expression on freshly isolated and activated CD4
+ T cells
was assessed by FCM and RT-PCR. In FCM analysis, T cells were
stained with anti-mouse Tim-4-PE or specific FITC-labeled rat
IgG2a isotype control. For RT-PCR analysis, total RNA was
isolated from purified CD4
+ T cells and the expression of Tim-1,
Tim-3 and Tim-4 was tested as described[18]. The primers used
were presented in Table S1.
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CD4
+ T cells (2610
5/well) were cultured in RPMI1640 medium
containing anti-CD3 and anti-CD28 mAbs and different concen-
tration of anti-Tim-4 mAb (1, 5, 10 mg/ml) or PBS or control rat
IgG1, with or without Tim-1-Fc (5 mg/ml). T-cell proliferation was
measured 72 h later by
3H thymidine incorporation as described
above. The supernatants were collected for cytokine detection.
MLR assays
B/6 mouse CD4
+ T cells (2610
5/well) were co-cultured with
BALB/c mouse DCs at the indicated ratios with or without Tim-1-
Fc (0,5,10 mg/ml) in5% CO2 at 37uC for72 h.T-cellproliferation
was measured by
3H thymidine incorporation as described above.
MLR supernatants were collected for cytokine detection.
In the experiments measuring secondary MLR responses, B/6
splenic CD4
+ T cells (2610
5/well) were first incubated with
irradiated (30Gy) BALB/c mouse DCs at a fixed stimulator:re-
sponder cell ratio (1:10) in the presence or absence of Tim-1-Fc (0,
5, 10 mg/ml) (primary MLR). After three days, residual cells were
incubated with FITC-conjugated anti-H-2
d mAb (BD Pharmin-
gen), and H-2d
+ BALB/c cells were removed by the MACS using
anti-FITC-microbeads (Miltenyi Biotech). The recovered B/6 T
cells were rested in culture medium for a further two days and then
restimulated with irradiated (30Gy) splenocytes from BALB/c or
C3H mice for 72 h (secondary MLR). T-cell proliferation was
measured by
3H thymidine incorporation as described above.
Signal pathways triggered by Tim-1-Fc exploring
CD4
+ T cells were stimulated by incubation with anti-CD3
(2 mg/ml) and anti-CD28 (1 mg/ml) mAbs together with hIgG1
(10 mg/ml) or Tim-1-Fc (10 mg/ml) for indicated time. The cells
were collected and lysed as described[19]. Briefly, twenty
micrograms of each sample was subjected to SDS-PAGE and
electrophoretic transfer to nitrocellulose membranes. Membranes
were immunoblotted with p-AKT, p-ERK1/2, or total ERK1/2
antibodies. The bound antibodies were detected by appropriate
HRP-conjugated anti-rabbit IgG. Quantification of protein levels
were performed by densitometric analysis.
Heart transplantation
Cervical heterotopic heart transplantation from BALB/c donors
into B/6 mice was performed as described[20]. Recipient mice
were injected intraperitoneally daily with 10 mg/kg of Tim-1-Fc
or hIgG1, or equal volume of PBS at day 0–6 post-operation
(POD 0–6). The contraction of heart grafts was monitored daily by
two independent observers without prior knowledge of the
treatment protocol. The complete cessation of cardiac contraction
was defined as the endpoint.
Histopathological examination and RT-PCR assays in
allografts
Cardiac grafts were harvested on POD 7 and fixed in 10%
formalin and embedded in paraffin. Sections were cut at 4 mm,
and were counterstained for 1 min with hematoxylin eosin.
Intragraft expression of IL-2, IFN-c, IL-4, IL-10, CD11b, CD3
and Foxp3 mRNA were analyzed using RT-PCR as de-
scribed[18]. The primers used were presented in Table S1.
Transcript levels were calculated according to the 2
2DDCt
method[21].
Statistical analysis
All values were expressed as means 6 SD. For all data, normal
versus non-normal distribution was assessed using the Shapiro-
Wilk test and by visual examination of histograms. Homogeneity
of variances was assessed by Levene test. For comparison of more
than two variants with a normal distribution, one-way ANOVA
analysis was used and followed by post hoc pair-wise comparisons
using the Bonferroni correction. For comparison of more than two
variants with a non-normal distribution, the Kruskal-Wallis test
was used and followed by post hoc pair-wise comparisons using the
Mann-Whitney test[22]. All of the above tests were performed
using SPSS13.0 software. A P value of ,0.05 was considered to be
statistically significant.
Results
Tim-1-Fc binds to Teffs but not nTregs or DCs through a
novel ligand other than Tim-4
To identify the binding activity of Tim-1-Fc to different mouse cell
types, BM derived DCs, nTregs and CD4
+CD25
2Tc e l l sw e r e
prepared or isolated from B6 mice. There wasno detectable binding of
Tim-1-Fc to DCs or nTregs, even after activation (Figure 1A and B).
However, upon stimulation with anti-CD3 and anti-CD28 mAbs for
72 h, CD4
+CD25
2T cells showed a distinct peak shift compared with
the hIgG1 control and this binding could not be abolished by anti-
Tim-4 mAb (Figure 1C). These results suggested Tim-1-Fc selectively
binds to CD4
+ Teffs through a novel ligand other than Tim-4.
Tim-1-Fc inhibits the activation and proliferation of Teffs
but not nTergs
To further determine the effect of Tim-1-Fc on Teffs and
nTregs, we compared the proliferation of purified CD4
+ T cells in
response to stimulation by anti-CD3 and anti-CD28 mAbs in the
presence or absence of Tim-1-Fc. Interestingly, we found that
Tim-1-Fc at a concentration of 5 mg/ml was able to significantly
inhibit the proliferation of CD4
+ T cells, and more pronounced at
concentration of 10 mg/ml, compared with PBS or control hIgG1
treatment (Figure 2A). Dose-dependent inhibition of CD4
+ T cell
division by Tim-1-Fc was confirmed by FCM of CFSE dilutions
(Figure 2B). Furthermore, Tim-1-Fc treatment significantly
suppressed the production of IL-2 and IFN-c, while increased
the production of IL-10 (Figure 2C).
Expression of CD69 and CD25 are closely related to T cells
activation. To analyze whether Tim-1-Fc inhibit T cell activation, the
expression of CD69 and CD25 were measured using FCM.
Stimulation of CD4
+ T cells with anti-CD3 and anti-CD28 mAbs
resulted in high expression of CD69 and CD25 on the majority of T
cells. However, CD69 and CD25 expression was markedly inhibited in
the presence of Tim-1-Fc (Figure 2D). Together, these results provide
strong evidence that Tim-1-Fc can also inhibit Teffs responses.
Previous study has shown that immunostimulatory Tim-1-
specific antibody (3B3) deprograms Tregs and prevents transplant
tolerance[12], while immunosuppressive Tim-1-specific antibody
(RMT1-10) enhances the function of nTregs and inhibits cardiac
Figure 1. Expression of a binding partner for Tim-1 on CD4
+ effector T cells. Unstimulated or 72 h LPS (100 ng/ml)-stimulated DCs (A), anti-
CD3, anti-CD28 mAbs and IL-2 (200 IU/ml)-stimulated CD4
+CD25
+Tregs (B) and anti-CD3 (2 mg/ml), CD28 (1 mg/ml) mAbs-stimulated CD4
+CD25
2 T
cells (C) were stained with 5 mg/ml control human IgG1 (gray line) or Tim-1-Fc (black line), followed by anti-human IgG1 Fc-FITC and subjected to
FCM analysis. Anti-Tim-4 mAb (10 mg/ml, dotted line) were added to block the possible Tim-1-Tim-4 interaction.
doi:10.1371/journal.pone.0021697.g001
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determine the influence of Tim-1-Fc on nTregs. Thus naı ¨ve
CD4
+CD25
+ T cells were isolated and cultured with anti-CD3 and
anti-CD28 mAbs plus IL-2 in the presence or absence of Tim-1-Fc
for three days. Unlike the CD4
+ T cells, addition of Tim-1-Fc into
the cultures did not inhibit nTregs proliferation (Figure 2E) or
Foxp3 expression (Figure 2F).
Tim-1 cross-linking with a novel ligand on T cells other
than Tim-4
Previous studies showed that Tim-4 is expressed on APCs, but
not on either naive or activated/polarized T cells[4,5,6,7,8,9]. To
further rule out the possibility that the observed inhibitory effect of
Tim-1-Fc on CD4
+ T cells is mediated by engagement with Tim-
4, we measured Tim-4 expression on CD4
+ T cells by both RT-
PCR and FCM. As shown in Figure 3A–C, neither freshly isolated
nor activated CD4
+ T cells showed detectable Tim-4. The data
indicate that the observed inhibition of CD4
+ T cell responses
(Figure 2A–D) by Tim-1-Fc was unlikely mediated by Tim-4. In
support of this, addition of anti-Tim-4 mAb failed to prevent Tim-
1-Fc-mediated inhibition on proliferation or cytokine production
of anti-CD3 and anti-CD28 mAbs-activated CD4
+ T cells
(Figure 3D and E). These results further indicate that Tim-1-Fc
can inhibit CD4
+ T cell responses by mechanisms independent of
Tim-4. The data also implicate the presence of a novel Tim-1
ligand on CD4
+ T cells.
Tim-1-Fc suppresses allo-MLR and induces T cell
hyporesponsiveness
We next assessed the inhibitory effect of Tim-1-Fc on CD4
+
T cell alloresponses by in vitro MLR assay. Mature DCs from
BALB/c mice potently provoked the proliferation of B/6 CD4
+
T cells (Figure 4A). However, the proliferation was significantly
inhibited by Tim-1-Fc in a dose-dependent manner. Tim-1-Fc
also significantly inhibited the production of IL-2, IFN-c,w h i l e
increased the production of IL-10 (Figure 4B). These results
demonstrate that Tim-1-Fc can effectively inhibit allo-MLR.
The ability of Tim-1-Fc to induce T cell hyporesponsiveness
to alloantigen restimulation was investigated. CD4
+ T cells
(2610
5/well) from B/6 mice primed with BALB/c DCs in the
presence or absence of Tim-1-Fc in primary MLR for 3 days,
and the responses of primed CD4
+ T cells to BLAB/c or C3H
(third-party) were measured in secondary MLR. Primed B6
CD4
+ T cells strongly proliferated in response to stimulation
with C3H splenocytes, regardless of whether Tim-1-Fc was
added in the primary MLR (Figure 4C). However, the
secondary response to BALB/c splenocytes of B/6 CD4
+ T
cells primed in the presence of Tim-1-Fc was significantly
reduced compared to those primed without Tim-1-Fc
(Figure 4D), and could not be restored by addition of IL-2
(Figure 4E). These results indicate that Tim-1-Fc treatment
induced donor specific T cell hyporesponsiveness in vitro.
Tim-1-Fc inhibits AKT and ERK1/2 phosphorylation in
mouse T cells
As extracellular signal-regulated protein kinase (ERK) kinas-
es[24,25] and AKT[26,27] were important downstream signal
molecular included upon TCR and CD28 engagement, we next
assessed the effect of Tim-1-Fc treatment on cell signal
transduction. As shown in Figure 5, the phosphorylation of
AKT and ERK1/2 stimulated by anti-CD3 and anti-CD28 mAbs
was significantly reduced by Tim-1-Fc treatment in CD4
+ T cells.
These results demonstrate that Tim-1-Fc affects both the MAP
and AKT kinase signaling pathways, which may be at least one of
mechanisms for the anti-proliferation activity of Tim-1-Fc.
Tim-1-Fc prolongs allografts survival in a fully MHC-
mismatched cardiac transplant model
We then used a fully MHC-mismatched mouse heterotopic
cardiac transplantation model to test the potential of Tim-1-Fc to
prevent allograft rejection. BALB/c hearts were transplanted to
B/6 recipients treated with daily injection of Tim-1-Fc (10 mg/
kg/day) from POD 0–6. Control recipients were similarly treated
with PBS or hIgG1. Recipients treated with Tim-1-Fc showed
significantly prolonged allograft survival (17.161.1 days) com-
pared to those treated with PBS (6.560.5 days; P,0.01) or hIgG1
(6.760.4 days; P,0.01, Figure 6A). Histological analysis of heart
grafts at POD 7 revealed severe mononuclear cell infiltration and
myocardial necrosis in the control groups, whereas almost normal
tissue structure with minimal mononuclear cell infiltration was
seen in Tim-1-Fc-treated mice (Figure 6B). These results indicate
that Tim-1-Fc could effectively ameliorate histological damage
and significantly prolong allograft survival.
Tim-1-Fc inhibits leukocytes infiltration in the allograft
and Th1 cytokines expression in the serum
RT-PCR analysis was performed to further understand the
intragraft gene expression changes after Tim-1-Fc treatment,
which significantly decreased intragraft CD11b (macrophages and
neutrophils), CD3 (T cells) and IL-2, IFN-c, while increased IL-10,
and slightly increased IL-4 and Foxp3 gene expression compared
with those in controls (Figure 6C). Moreover, Tim-1-Fc treatment
significantly reduced the secretion of IL-2 and IFN-c, while
increased IL-10 levels in the serum (Figure 6D). Considering that
Tim-1-Fc was able to inhibited Th1 cytokines production while
promote Th2 responses in vivo, whether the administration of
Tim-1-Fc results in increased production of antibody to allogenic
heart should be assessed. However, we did not detect significant
increase of alloantibody between hIgG1-Fc- and Tim-1-Fc-treated
mice on POD 7 or 14 after transplantation (Figure S3).
Tim-1-Fc induced hyporesponsiveness of CD4
+ T cells to
alloantigen
Next, we isolated the splenic CD4
+ T cells from either Tim-1-Fc
treated or control B6 mice to explore their responses to alloantigen-
Figure 2. Tim-1-Fc inhibits the activation and proliferation of Teffs but not nTergs. Splenic CD4
+ T cells (2610
5/well) were purified from
C57BL/6 mice and were stimulated by anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) mAbs in the presence of Tim-1-Fc (1, 5, 10 mg/ml) or control PBS or
hIgG1 for 72 h. Proliferation was measured by
3H thymidine uptake (A) and CSFE (B). Supernatants were obtained for cytokine ELISA (C). CD4
+ T cells
(2610
5/well) were stimulated with anti-CD3, anti-CD28 mAbs or together with Tim-1-Fc (10 mg/ml) in 96-well plates for 48 h, then were harvested to
stain with anti-CD69, CD25-PE and analyzed by FCM. Data were representative of three experiments (D). Freshly isolated CD4
+CD25
+ regulatory T
cells were stimulated with anti-CD3, anti-CD28 mAbs (100 ng/ml for each) and IL-2 (200 IU/ml) in the presence of Tim-1-Fc (1, 5, 10 mg/ml) for 72 h,
the proliferation and Foxp3 expression of nTregs were assessed by
3H thymidine incorporation (E) or RT-PCR (F). *P,0.05, **P,0.01 in comparison
with controls.
doi:10.1371/journal.pone.0021697.g002
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21697Figure 3. Tim-4 is not expressed by mouse T cells. Freshly isolated or anti-CD3 (2 mg/ml), anti-CD28 (1 mg/ml) mAbs activated CD4
+ T cells were
tested by RT-PCR (A, B) and stained with anti-mouse Tim-4-PE (black line) or specific isotype control (gray line) and subjected to FCM analysis. Data
were representative of three experiments (C). CD4
+ T cells were cultured with anti-CD3 and anti-CD28 mAbs in the presence of PBS or control rat
IgG1 or Tim-1-Fc (5 mg/ml) together with anti-Tim-4 mAb (1, 5, 10 mg/ml) for 72 h. T cells proliferation and cytokines secretion were detected by
3H
thymidine uptake (D) or ELISA (E).
doi:10.1371/journal.pone.0021697.g003
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e21697Figure 4. Tim-1-Fc inhibits allo-MLR and induces T cell hyporesponsiveness. CD4
+ T cells (2610
5/well) were cocultured with BALB/C
derived DCs at indicated ratios (1:40, 1:20, 1:10) for 72 h, Tim-1-Fc (5, 10 mg/ml) was added to the culture at the beginning. Cell proliferation and
cytokines production were evaluated by
3H-thymidine incorporation (A) and ELISA (B). C57BL/6 splenic CD4
+ T cells (2610
5/well) were incubated at a
fixed stimulator:responder cell ratio (1:10) with irradiated allogeneic DCs in primary MLR. After three days, DCs were removed by autoMACS selection
of H-2
d cells. The CD4
+ T cells were rested in culture medium for a further two days, and then restimulated with irradiated C3H (H-2
k, third-party)
splenocytes (C), BALB/c derived splenocytes (D), or plus 20 IU/ml IL-2 (E) for 72 h (secondary MLR) at different stimulator:responder cell ratio. Cell
proliferation was determined by
3H thymidine incorporation. *P,0.05, ** P,0.01 from the group without Tim-1-Fc treatment.
doi:10.1371/journal.pone.0021697.g004
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proliferation was significantly inhibited in Tim-1-Fc treated groups
72 h after restimulation, as compared to the controls. In concert
with this, IL-2 and IFN-c production was significantly inhibited,
while the production of IL-10 was increased (Figure 7B). This data
further documented that Tim-1-Fc induces hyporesponsiveness of
CD4
+ T to alloantigen (Figure 4).
Tim-1-Fc shifts the balance between Teffs and Tregs
To further identify the influence of Tim-1-Fc on Foxp3
expression in recipient mice, CD4
+ T cells were isolated from
Tim-1-Fc treated mice or controls on POD 7 to test the percentage
of CD4
+Foxp3
+ T cells. As shown in Figure 7C, Tim-1-Fc
triggered a significant increase in the percentage of CD4
+ T cells
expressing a regulatory phenotype in the spleen (16.3%62.3% vs.
8.2%61.0%; P,0.01), but there was no significant difference in
the Foxp3
high cells frequency between the control and treated
mice. Given the inhibited proliferation capacity of CD4
+ T
compartment (Figure 2A), the increased frequency of Foxp3
low
cells might be a consequence of decreased number of Teffs, but
not the expansion of Tregs. However, these data strongly suggest
Tim-1-Fc prolongs allograft survival by shifting the balance
between Teffs and Tregs.
Discussion
In the study presented herein, we demonstrated that Tim-1-Fc
can selectively bind to Teffs through a novel ligand other than
Tim-4. In vitro administrating Tim-1-Fc significantly inhibited the
activation and proliferation of purified CD4 T cells, and their
response to allogenic DCs. The inhibition of AKT and ERK1/2
phosphorylation is, at least, one of the mechanisms responsible for
this APC/Tim-4-independent inhibitory effect. But Tim-1-Fc did
not inhibit the proliferation or Foxp3 expression of nTregs. In vivo
administration of Tim-1-Fc effectively prolonged cardiac allograft
survival in a fully MHC-mismatched strain combination, this was
associated with impaired Th1 response and preserved Th2 and
nTregs function. Importantly, the proportion of Foxp3
+ cells in
splenic CD4
+ T cells was increased, thus shifting the balance
toward regulators. These results not only demonstrate the presence
of an unidentified Tim-1 ligand capable of suppressing T cell
activation upon biding to Tim-1-Fc, but also suggest the potential
of Tim-1-Fc as a therapeutic agent for preventing allograft
rejection.
Among T cells, Tim-1 was initially found to be predominantly
expressed by Th2 cells, but accumulating data revealed that it is
also expressed on murine and human Th1 cell lines, suggesting
that Tim-1 may function as a global adjuvant of T-cell
responses[28]. As a cognate ligand for Tim-1, Tim-4 was
previously found to be expressed on mature, activated DCs and
macrophages, but not on T cells, and Tim-4/Tim-1 engagement
was shown to promote T-cell expansion and survival, suggesting
that the Tim-1 pathway naturally functions as a potent T cell
stimulator[5,6,7]. However, these may not always be the case,
recent studies revealed that Tim-4 and Tim-1 could deliver either
a positive or negative signal into T cells. Meyers et al[4] found that
a higher dose (5 mg/ml) of Tim-4-Ig consistently led to an increase
in T cell proliferation upon TCR ligation, whereas a lower
concentration (1 mg/ml) of Tim-4-Ig inhibited T cell proliferation.
This dose-dependent inhibition could be explained by several
different mechanisms: It is possible that Tim-4 may engage
another, high-affinity ligand on the surface of T cells that delivers a
negative signal into T cells [10]. Alternatively, the effect of Tim-1
may depend on the ligand density and extent of engagement by
Tim-4, in which Tim-1 delivers an inhibitory signal at lower levels
of engagement and a positive signal at higher concentrations,
similar to the agonist-antagonist phenomenon noted with altered
peptide ligands[29]. Additionally, it was found that two monoclo-
nal antibodies (clone 3B3 and clone RMT1-10) specific for the IgV
domain of Tim-1 mediate opposite effects on T cell activation, in
which the high avidity clone 3B3 enhances Th1 responses and
prevented transplant tolerance induction, while the low avidity
clone RMT1-10 prevents cardiac allograft rejection and induces
Treg-dependent peripheral tolerance. Although these studies
indicate that Tim-1 may serve as either a positive or a negative
T cell costimulatory molecule depends on the ligand binding
avidity, it remains unclear whether Tim-1 can also regulate T cell
activation by engaging other ligands or receptors.
Using purified DCs, nTregs and CD4
+CD25
2 T cells, we
observed that Tim1-1-Fc can selectively bind to Teffs and
significantly inhibit CD4 T cells activation and proliferation in
response to anti-CD3/CD28 mAbs. Although a previous study
showed detectable Tim-4 mRNA in human CD4
+ and CD8
+ T
cells[30], we could not detect Tim-4 on mouse CD4 T cells by
either FCM or RT-PCR, which is consistent with many other
studies[4,6,10,31]. Moreover, anti-Tim-4 blocking antibodies
could not prevent the effect of Tim-1-Fc, further supporting the
possibility that the observed inhibition of CD4 T cells activation is
Tim-4-independent and mediated by engaging with an unknown
Tim-1 receptor that is expressed on CD4 T cells. The significant
inhibition of AKT and ERK1/2 phosphorylation in CD4 T cells
suggests that the AKT and MAP kinase signaling pathways are
likely to be at least one of mechanisms for the anti-proliferative
effect of Tim-1-Fc.
Previous study[4] has revealed that in vivo administration of
Tim-1-Ig, a recombinant mouse Tim-1 extracellular domain and
human IgG1-Fc fusion protein, resulted in higher levels of IL-4,
IL-10 and lower levels of IL-2, IFN-c in SJL/J mice. In our study,
Figure 5. Tim-1-Fc inhibits AKT and ERK1/2 phosphorylation in mouse T cells. C57BL/6 mouse CD4
+ T cells (2610
6/well) were stimulated by
anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) mAbs plus 10 mg/ml Tim-1-Fc or control human IgG1 for indicated times. Whole-cell lysates were
analyzed for kinase phosphorylation by western blotting. Data were representative of three separate experiments.
doi:10.1371/journal.pone.0021697.g005
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21697Figure 6. Tim-1-Fc prolongs cardiac allograft through inhibiting Th1 cytokines expression and leukocytes infiltration. Heterotopic
heart grafts were transplanted from BALB/c mice into C57BL/6 recipients. The recipients were treated with PBS (n=10), hIgG1 (10 mg/kg, n=10) or
Tim-1-Fc (10 mg/kg, n=10) starting on post operation day (POD) 0 for seven consecutive days. Rejection was defined as cessation of a palpable
impulse. Survival rates were compared using log-rank test (A). Hematoxylin eosin staining (B) of representative heart allografts harvested at POD 7
from mice treated with PBS, control hIgG1 or Tim-1-Fc (original magnification 6200). Cardiac allografts and blood were harvested on POD 7 from
recipients. Intragraft expression of IL-2, IFN-c, IL-4, IL-10, CD11b, CD3 and Foxp3 mRNA was measured by RT-PCR (C) and normalized against GAPDH.
Serum levels of IL-2, IFN-c, IL-4 and IL-10 were tested by ELISA (D). *P,0.05, ** P,0.01 in comparison with controls.
doi:10.1371/journal.pone.0021697.g006
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e21697the impaired Th1 response may contribute to the prolonged
cardiac allograft survival, however, we did not detect significant
increase of alloantibody between hIgG1-Fc- and Tim-1-Fc-treated
mice on POD 7 or 14 after transplantation. Previous studies have
demonstrated that heart graft rejection in this model is T cell-
dependent[32] and CD4
+ T cells are both necessary and sufficient
to mediate acute cardiac allograft rejection in mice[33,34].
Although alloantibodies contribute to graft rejection, the produc-
tion of alloantibodies is predominantly T cell-dependent. Thus,
the graft rejection in Tim-1-Fc-treated mice is likely due to
incomplete suppression of anti-donor T cell responses. Further-
more, Tim-1-Fc successfully shifted the balance towards regula-
tors, as evidenced by the increased proportion of Foxp3 positive
cells in recipients’ spleens, which may also promote the immune
tolerance[23]. In view that the inhibited proliferation capacity of
effector CD4
+ T compartment, the increased frequency of
Foxp3
low cells might be a consequence of relatively decreased
number of Teffs, but not the expansion of Tregs, as evidenced by
the stable frequency of Foxp3
high cells. Besides, we also observed
that stimulation of CD4
+CD25
2T cells with anti-CD3 and anti-
CD28 mAbs in the presence of TGF-b1 significantly increased the
frequency of CD4
+Foxp3
+ T cells, however, the addition of
various concentrations of Tim-1-Fc had no additional effect,
suggesting that Tim-1-Fc does not convert CD4
+CD25
2T cells
into CD4
+Foxp3
+ Tregs directly (data not shown). Together, the
data strongly suggest that Tim-1-Fc prolonged allograft survival by
reducing the Teffs but not by increasing Tregs, however, the
balance of Teffs/Tregs was shifted towards regulators.
In addition to Tim-4, phosphatidylserine and leukocyte mono-
Ig–like receptor 5 (LMIR5)/CD300b were found to interact with
Tim-1[35,36]. Because phosphatidylserine is an apoptotic cell
surface-specific epitope[37], it is unlikely to be involved in the
inhibitory effect of Tim-1-Fc on T cells. In addition, LMIR5 is also
unlikely to be responsible for Tim-1-Fc-mediated inhibition of
Figure 7. Tim-1-Fc induces hyporesponsiveness of CD4
+ T cells to alloantigen and shifts the balance between Teffs and Tregs. CD4
+
T cells (2610
5/well) purified from C57BL/6 recipient treated with PBS, hIgG1 and Tim-1-Fc for 7 days were cocultured with BALB/C derived DCs at
indicated ratios (1:40, 1:20, 1:10) for 72 h. Cell proliferation and cytokines production were evaluated by
3H-thymidine incorporation (A) and ELISA (B).
*P,0.05, ** P,0.01 in comparison with controls. (C) The proportion of CD4
+Foxp3
+ T cells in C57BL/6 recipient splenic CD4
+ T cells was determined
by FCM analysis. The frequency of Foxp3
high and Foxp3
low cells was labled. Data were representative of three experiments.
doi:10.1371/journal.pone.0021697.g007
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PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e21697CD4 T-cell activation in the absence of APCs, as this molecule is
mainly expressed in myeloid cells, but not T cells[38,39].
However, we detected other members of LMIR family such as
LMIR1 and LMIR3, which are immunoreceptor tyrosine-based
inhibitory motif-containing inhibitory receptors, are expressed by
mouse T cells in the mRNA level (data not shown), whether they
act as the endogenous inhibitory ligands for Tim-1 needs to be
further explored.
In summary, we show that Tim-1-Fc mediates potent inhibition
of T cells activation and significantly prolongs allograft survival in
a MHC-mismatched murine cardiac transplantation model. This
could be the selective binding of Tim-1-Fc to Teffs through a novel
ligand other than Tim-4. These results further illustrate the
importance of the Tim-1 and Tim-1-binding partner interaction in
the regulation of immune responses and point to the possibility of
developing immunosuppressive therapies to prevent allograft
rejection.
Supporting Information
Figure S1 Western blot for Tim-1-Fc. Immunoblot analysis
for purified Tim-1-Fc was performed with mouse anti-human
IgG1 Fc mAb and rat anti-mouse mAb conjugated to horseradish
peroxidase, followed by enhanced chemiluminescence.
(TIF)
Figure S2 Anti-Tim-4 inhibits ligand binding to Tim-4.
DCs from BALB/c mice were stimulated by LPS (100 ng/ml) and
mouse Tim-1-Ig (eBioscience, 5 mg/ml) with or without anti-Tim-
4 (10 mg/ml) for 3 days, then they were stained with anti-human
IgG1 Fc-FITC and subjected to FCM analysis. Histograms
represent Tim-1-Ig staining (black line) versus human IgG1
control (grey line) staining. Data are representative of two
experiments.
(TIF)
Figure S3 Production of donor-reactive Ab in C57BL/6
recipients of BALB/c cardiac allografts. On POD 7 (A) and
14 (B) posttransplant, serum from PBS-, hIgG1- and Tim-1-Fc-
treated (n=6 for each) recipients was diluted, and each dilution
was assayed by FCM for activity against naı ¨ve BALB/c
splenocytes to determine the titer. Individual titers are shown
with the mean and standard deviation represented by the bar. For
each test day posttransplant, P.0.05 when comparing titers of
donor-reactive Abs between Tim-1-Fc-treated and control mice.
(TIF)
Table S1 Primers used in the study.
(DOC)
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